Enfortumab Vedotin + Pembrolizumab
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bladder Cancer
Conditions
Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Trial Timeline
Mar 31, 2025 → Jan 31, 2028
NCT ID
NCT06470282About Enfortumab Vedotin + Pembrolizumab
Enfortumab Vedotin + Pembrolizumab is a phase 1/2 stage product being developed by Astellas Pharma for Bladder Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06470282. Target conditions include Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8.
What happened to similar drugs?
10 of 20 similar drugs in Bladder Cancer were approved
Approved (10) Terminated (1) Active (9)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07475806 | Phase 2 | Recruiting |
| NCT06906822 | Phase 2 | Recruiting |
| NCT06809140 | Phase 2 | Recruiting |
| NCT06470282 | Phase 1/2 | Recruiting |
| NCT05756569 | Phase 2 | Recruiting |
| NCT05239624 | Phase 2 | Recruiting |
| NCT04225117 | Phase 2 | Active |
Competing Products
20 competing products in Bladder Cancer